NCT07266428 2026-04-16
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Ottimo Pharma Limited
Phase 1/2 Recruiting
Clinical Trials
20 trialsNCT06741644 2026-04-15
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Recruiting
NCT07509684 2026-04-13
A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT04626635 2026-04-09
COMBINE-EGFR-1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05083481 2026-04-08
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT05773820 2026-04-01
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT07222969 2026-03-23
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
Vibrant Sciences Limited
Phase 1/2 Recruiting
NCT06736704 2026-03-13
SNV4818 in Participants With Advanced Solid Tumors
Pikavation Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06819735 2026-03-10
DOMISOL
Domain Therapeutics SA
Phase 1/2 Recruiting
NCT07459998 2026-03-10
SKB103 for Injection in Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07460375 2026-03-10
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Not yet recruiting
NCT06242691 2026-03-06
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT05951608 2026-03-05
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Akeso
Phase 1/2 Active not recruiting
NCT07328217 2026-02-11
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Dizal Pharmaceuticals
Phase 1/2 Recruiting
NCT07359066 2026-02-05
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT06697197 2026-02-03
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07380386 2026-02-02
SKB105 for Injection in Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05867420 2026-01-27
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
AskGene Pharma, Inc.
Phase 1/2 Recruiting
NCT07093970 2026-01-22
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
Lepu Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT06556108 2026-01-20
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Xinqiao Hospital of Chongqing
Phase 1/2 Completed